Entero Regains Nasdaq Compliance With Grid AI Acquisition
Rhea-AI Summary
Entero Therapeutics (NASDAQ:ENTO) announced on October 30, 2025 that it acquired 100% of Grid AI Corp., has made Grid AI a wholly owned subsidiary, and has regained compliance with Nasdaq Listing Rule 5550(b)(1). The company describes its platform as positioned at the intersection of AI, hyperscale data centers, power grids and global infrastructure to pursue grid-edge orchestration and AI-driven infrastructure optimization.
The release also notes forward-looking statements and specifically references the need to obtain shareholder approval for common stock underlying preferred stock issued in the acquisition and uncertainty about future results.
Positive
- Acquired 100% of Grid AI Corp.
- Regained Nasdaq compliance under Rule 5550(b)(1)
- Grid AI added as wholly owned subsidiary
- Positioning in AI and hyperscale data center market
Negative
- Shareholder approval required for common stock underlying issued preferred stock
- Forward-looking outcomes may differ materially from expectations
News Market Reaction 2 Alerts
On the day this news was published, ENTO declined 0.67%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $59K from the company's valuation, bringing the market cap to $9M at that time.
Data tracked by StockTitan Argus on the day of publication.
BOCA RATON, FL / ACCESS Newswire / October 30, 2025 / Entero Therapeutics, Inc. ("Entero" or the "Company") (NASDAQ:ENTO) is pleased to announce that, as a result of the acquisition of
Entero's publicly‑listed platform now sits at the intersection of AI, data centers, power grids, and global infrastructure. The acquisition of Grid AI, now operating as a wholly‑owned subsidiary of Entero, enables the Company to participate in one of the most significant secular growth arenas of the coming decade: hyperscale data centers, grid‑edge orchestration, and AI‑driven infrastructure optimization.
Forward‑Looking Statements
This press release contains forward‑looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the strategic benefits of the acquisition, the integration of Grid AI, the ability to maintain compliance with Nasdaq's listing criteria in connection with the Grid AI acquisition and otherwise, the ability to obtain shareholder approval of the common stock underlying the preferred stock issued in the Grid AI acquisition, expected future operating results, market opportunities, and the Company's growth strategy. Actual results may differ materially due to risks and uncertainties. The Company undertakes no obligation to update forward‑looking statements except as required by law.
About Entero Therapeutics, Inc.
Entero Therapeutics (NASDAQ:ENTO) is a publicly listed company. The Company's programs address significant unmet needs in gastrointestinal (GI) health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following the acquisition of Grid AI, the Company is continuing these prior operations and is also repositioning into the infrastructure, AI and data‑centre orchestration space. Entero operates Grid AI as a wholly‑owned subsidiary and intends to leverage its public‑market listing and corporate resources to scale the new venture.
About Grid AI
Grid AI is an AI‑driven, grid‑edge software and device orchestration platform enabling business, utility, and hyperscaler customers to forecast, optimize, and dispatch flexible demand, DERs and compute assets. The platform supports major ML frameworks, offers rapid scale across cloud GPU/CPU infrastructure, and is designed to deliver SaaS‑like recurring revenue.
Investor & Media Contacts:
Entero Investor Relations
investors@enterothera.com
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Entero (ENTO) announce on October 30, 2025 about Grid AI?
How did the Grid AI acquisition affect Entero's Nasdaq status (ENTO)?
What strategic markets does Entero (ENTO) say the Grid AI deal targets?
Does the Entero (ENTO) announcement mention shareholder approvals?
Are there risks noted in Entero's (ENTO) Grid AI acquisition announcement?
